38 related articles for article (PubMed ID: 36637153)
1. Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women.
Eriksson M; Czene K; Conant EF; Hall P
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33467653
[TBL] [Abstract][Full Text] [Related]
2. Host, reproductive, and lifestyle factors in relation to quantitative histologic metrics of the normal breast.
Abubakar M; Klein A; Fan S; Lawrence S; Mutreja K; Henry JE; Pfeiffer RM; Duggan MA; Gierach GL
Breast Cancer Res; 2023 Aug; 25(1):97. PubMed ID: 37582731
[TBL] [Abstract][Full Text] [Related]
3. A novel preclinical model of the normal human breast.
Wilby AJ; Cabral S; Zoghi N; Howell SJ; Farnie G; Harrison H
J Mammary Gland Biol Neoplasia; 2024 May; 29(1):9. PubMed ID: 38695983
[TBL] [Abstract][Full Text] [Related]
4. The Potential for Mammographic Breast Density Change as a Biosensor of Adjuvant Tamoxifen Therapy Adherence and Response.
Mullooly M; Gierach GL
JNCI Cancer Spectr; 2018 Nov; 2(4):pky072. PubMed ID: 30746510
[No Abstract] [Full Text] [Related]
5. FGF/FGFR1 system in paired breast tumor-adjacent and tumor tissues, associations with mammographic breast density and tumor characteristics.
Boraka Ö; Klintman M; Vallon-Christersson J; Zackrisson S; Hall P; Borgquist S; Rosendahl AH
Front Oncol; 2023; 13():1230821. PubMed ID: 37546410
[TBL] [Abstract][Full Text] [Related]
6. Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women.
Hammarström M; Gabrielson M; Crippa A; Discacciati A; Eklund M; Lundholm C; Bäcklund M; Wengström Y; Borgquist S; Bergqvist J; Eriksson M; Tapia J; Czene K; Hall P
Br J Cancer; 2023 Jul; 129(1):61-71. PubMed ID: 37149701
[TBL] [Abstract][Full Text] [Related]
7. Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.
Atakpa EC; Thorat MA; Cuzick J; Brentnall AR
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013091. PubMed ID: 34697802
[TBL] [Abstract][Full Text] [Related]
8. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
9. Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women.
Gabrielson M; Hammarström M; Bäcklund M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Int J Cancer; 2023 Jun; 152(11):2362-2372. PubMed ID: 36637153
[TBL] [Abstract][Full Text] [Related]
10. Baseline breast tissue characteristics determine the effect of tamoxifen on mammographic density change.
Gabrielson M; Hammarström M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Int J Cancer; 2024 Jul; 155(2):339-351. PubMed ID: 38554131
[TBL] [Abstract][Full Text] [Related]
11. Amount of stroma is associated with mammographic density and stromal expression of oestrogen receptor in normal breast tissues.
Gabrielson M; Chiesa F; Paulsson J; Strell C; Behmer C; Rönnow K; Czene K; Östman A; Hall P
Breast Cancer Res Treat; 2016 Jul; 158(2):253-61. PubMed ID: 27349429
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Eriksson M; Eklund M; Borgquist S; Hellgren R; Margolin S; Thoren L; Rosendahl A; Lång K; Tapia J; Bäcklund M; Discacciati A; Crippa A; Gabrielson M; Hammarström M; Wengström Y; Czene K; Hall P
J Clin Oncol; 2021 Jun; 39(17):1899-1908. PubMed ID: 33734864
[TBL] [Abstract][Full Text] [Related]
13. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
14. Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.
Kim WH; Cho N; Kim YS; Yi A
Eur Radiol; 2018 Aug; 28(8):3176-3184. PubMed ID: 29626240
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
